Yokogawa to Supply Energy Management System for Yuri Green Hydrogen Project in Australia
5.9.2023 03:00:00 EEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Australia has received an order from Monford Group Pty Ltd. to supply an energy management system (EMS) for the initial phase (“phase 0”) of the Yuri Green Hydrogen Project (hereafter, Yuri), which is constructing an industrial-scale renewable hydrogen production complex in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904401589/en/
Conceptual drawing showing the Yuri project facilities at the completion of phase 0. The existing YPF ammonia plant is in the foreground and the solar plant is in the background. (Source: ENGIE S.A.)
The Yuri project is being undertaken in the Pilbara region of Western Australia by Yuri Operations Pty Ltd, a joint venture between ENGIE Renewables Australia Pty Ltd and Mitsui & Co., Ltd. A consortium consisting of the engineering, procurement, construction and commissioning (EPCC) companies Technip Energies and Monford Group Pty Ltd. is constructing these facilities, which will consist of an 18-megawatt solar power plant, an 8-megawatt battery energy storage system (BESS), and a 10-megawatt electrolyzer. Using carbon-free solar energy, this facility will be able to produce up to 640 tons of green hydrogen per year. The hydrogen will be used as a feedstock to produce green ammonia at an adjacent ammonia plant operated by Yara Pilbara Fertiliser Pty Ltd (YPF). YPF is a wholly owned subsidiary of Yara International ASA, which is one of the world's largest producers of nitrogen-based mineral fertilizers.
For the control of the solar power plant, BESS, and electrolyzer, Yokogawa Australia will supply an EMS that is developed by Yokogawa Group company PXiSE Energy Solutions LLC. This EMS will be combined with an integrated control system (ICS) centering on the Collaborative Information Server solution that Yokogawa will also be providing for phase 0 of this project, under a separate contract*1. Once these systems are installed and integrated, the Yuri facility’s renewable energy production will be autonomously managed to ensure consistent stability and power quality based on the operating requirements of the adjacent ammonia plant, the weather, and other factors.
PXiSE’s grid control solutions have already been highly evaluated at a Horizon Power project in Western Australia*2. Horizon Power serves the largest power supply area in the world, and following a successful rollout in Onslow, the solutions will be adopted in 34 additional Horizon Power microgrids. Also, the ability of Yokogawa Australia's Technical Excellence Center in Perth, Western Australia, to provide technical support and engineering services backed by many years of experience in providing cutting-edge solutions to a wide range of industries in Australia was also evaluated.
Commenting on Yokogawa’s participation in this project, Koji Nakaoka, a Yokogawa senior vice president and head of the company's Energy & Sustainability Business Headquarters and Global Sales Headquarters, said, “In a world in which systems are becoming closely integrated, based on the system of systems (SoS) concept, we will contribute to our customer’s ESG management by offering high value-added solutions, including the integration of plant control and energy management systems to enable the timely control of complex power systems.”
*1 Yokogawa to Provide Integrated Control System for Australian Green Hydrogen Project - First-ever use in Australia of green hydrogen as feedstock for ammonia production – https://www.yokogawa.com/news/press-releases/2022/2022-11-30-01/
*2 Horizon Power and PXiSE Energy Solutions Successfully Operate World’s First 100% Solar-Plus-Storage-Only Community Grid https://pxise.com/horizon-power-and-pxise-energy-solutions-successfully-operate-worlds-first-100-solar-plus-storage-only-community-grid/
PXiSE DERMS used in 34 Horizon Power microgrids https://pxise.com/pxise-derms-used-in-34-horizon-power-microgrids/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 129 companies spanning 60 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904401589/en/
Contact information
PR Section
Integrated Communications Center
Yokogawa Electric Corporation
Yokogawa-pr@cs.jp.yokogawa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom